Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases

Reuters

2025/06/17

Spyre <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases

Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544096170"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544096170\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544096170?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544096170","market":"nz","top_or_hot":-1,"title":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre Therapeutics, Inc. <a href=\"https://laohu8.com/S/SYRE\">$(SYRE)$</a>, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-17 19:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Spyre <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Spyre Therapeutics, Inc. <a href=\"https://laohu8.com/S/SYRE\">$(SYRE)$</a>, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYRE","symbol_name":"SPYRE THERAPEUTICS INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL2NYgl5:1","article_id":"2544096170","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544096170","pubTimestamp":1750159845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases. Spyre Therapeutics, Inc. , a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYRE":"SPYRE THERAPEUTICS INC","BK4139":"生物科技"},"translate_title":"Spyre Therapeutics宣布TL1A抗体项目1期中期结果积极，并启动炎症和风湿病2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYRE":0.9},"content_text":"Spyre Therapeutics Announces Positive Interim Phase 1 Results for TL1A Antibody Programs and Launches Phase 2 Trials in Inflammatory and Rheumatologic Diseases\n    \n\n        Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spyre Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA11863) on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}